Hospital
Mercy Health Youngstown LLC
Mercy Health Youngstown LLC was paid $43.63M by Medicaid between Jan 2018 and Dec 2024, across 385 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoMERCY HEALTH YOUNGSTOWN LLC
WARREN, OH 44484
WARREN, OH 44484
33aNPI1629009964assigned 07/05/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$43.63M
24GClaims1,085,505
24DCodes billed385
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Ohio
Rank by total paid#3 of 6
Median peer was paid$22.82M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 120,479 | $3.95M | |
| 2019 | 128,852 | $4.32M | |
| 2020 | 83,327 | $4.30M | |
| 2021 | 100,539 | $5.18M | |
| 2022 | 119,178 | $5.47M | |
| 2023 | 300,368 | $11.25M | |
| 2024incomplete | 232,762 | $9.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 75,732 | 70,474 | $8.91M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 14% | 67,624 | 59,860 | $6.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 43,583 | 39,145 | $5.24M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 22,459 | 19,388 | $2.95M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.6% | 28,473 | 27,223 | $2.87M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.8% | 6,334 | 4,489 | $2.11M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 8,735 | 7,686 | $2.10M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 7,267 | 6,254 | $1.93M |
| 59025 | Fetal non-stress test | 1.7% | 4,416 | 1,306 | $757K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 1,496 | 1,353 | $713K |
| 80053 | Comprehensive metabolic panel | 1.3% | 54,777 | 45,452 | $550K |
| G0378 | Hospital observation service, per hour | 1.1% | 5,848 | 2,744 | $495K |
373 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 2,800 | $481K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,447 | $412K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,501 | $376K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,431 | $369K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,054 | $338K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,701 | $324K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,391 | $266K |
| 64483 | <1% | 578 | $240K | |
| 95811 | <1% | 308 | $189K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,079 | $176K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,438 | $174K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 250 | $164K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 9,470 | $158K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 69,289 | $156K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,559 | $140K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,848 | $138K |
| 64493 | <1% | 239 | $135K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,498 | $133K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,103 | $132K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,906 | $108K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 607 | $106K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,328 | $101K |
| 83605 | <1% | 18,219 | $100K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 389 | $95K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,311 | $88K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 357 | $81K |
| 36415 | Collection of venous blood by venipuncture | <1% | 63,080 | $81K |
| 12001 | <1% | 493 | $79K | |
| 47563 | <1% | 36 | $75K | |
| 84484 | <1% | 21,873 | $73K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 958 | $73K |
| 00731 | <1% | 1,712 | $72K | |
| 70491 | <1% | 234 | $72K | |
| 71271 | <1% | 406 | $61K | |
| 93970 | <1% | 430 | $61K | |
| 85027 | <1% | 9,638 | $61K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 622 | $58K |
| 71250 | <1% | 654 | $57K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,847 | $56K |
| 93971 | <1% | 916 | $56K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,011 | $54K |
| 80061 | Lipid panel | <1% | 4,533 | $51K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,157 | $50K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,856 | $50K |
| 95800 | <1% | 151 | $49K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 340 | $49K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 399 | $49K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,475 | $49K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 324 | $48K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,086 | $43K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 495 | $43K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 604 | $43K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,073 | $42K |
| 70496 | <1% | 154 | $41K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,810 | $39K |
| 94060 | <1% | 338 | $38K | |
| 86900 | <1% | 1,917 | $38K | |
| 96415 | <1% | 256 | $37K | |
| 62323 | <1% | 97 | $37K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 76 | $36K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 267 | $35K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,639 | $34K |
| 82728 | <1% | 2,162 | $34K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,435 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,335 | $34K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 70 | $34K |
| 76642 | <1% | 284 | $34K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,636 | $33K |
| 72131 | <1% | 563 | $33K | |
| 93976 | <1% | 338 | $33K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,316 | $33K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,534 | $32K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 677 | $31K |
| 76536 | <1% | 284 | $30K | |
| 76770 | <1% | 181 | $29K | |
| 93975 | <1% | 301 | $28K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 157 | $27K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,408 | $27K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 825 | $25K |
| 81001 | <1% | 35,321 | $24K | |
| 82607 | <1% | 1,751 | $24K | |
| 76830 | Ultrasound, transvaginal | <1% | 558 | $22K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,831 | $22K |
| 72100 | <1% | 1,159 | $21K | |
| 84439 | <1% | 2,059 | $21K | |
| 80305 | <1% | 2,095 | $21K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 355 | $19K |
| 96367 | <1% | 398 | $18K | |
| 74018 | <1% | 936 | $18K | |
| 80320 | <1% | 1,296 | $18K | |
| 94729 | <1% | 316 | $18K | |
| 94726 | <1% | 307 | $17K | |
| 86850 | <1% | 1,587 | $17K | |
| 73130 | <1% | 1,742 | $16K | |
| 73030 | <1% | 1,145 | $15K | |
| 99201 | <1% | 273 | $15K | |
| 83540 | <1% | 1,523 | $15K | |
| 73562 | <1% | 1,019 | $15K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,477 | $15K |
| 90714 | <1% | 1,029 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,758 | $14K |
| 83880 | <1% | 3,705 | $14K | |
| 97161 | <1% | 492 | $14K | |
| 73630 | <1% | 1,868 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,710 | $13K |
| 12011 | <1% | 73 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,155 | $13K |
| 12002 | <1% | 91 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,964 | $13K |
| 70486 | <1% | 369 | $12K | |
| 83735 | <1% | 6,085 | $12K | |
| 82950 | <1% | 819 | $12K | |
| 86803 | <1% | 561 | $12K | |
| 36591 | <1% | 339 | $11K | |
| 84630 | <1% | 769 | $11K | |
| 83690 | <1% | 15,704 | $11K | |
| 73502 | <1% | 672 | $11K | |
| 83550 | <1% | 1,440 | $10K | |
| 10060 | <1% | 64 | $10K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 471 | $10K |
| 84702 | <1% | 1,220 | $10K | |
| 86140 | <1% | 1,026 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,583 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 463 | $9K |
| 93017 | <1% | 103 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,580 | $8K |
| 87088 | <1% | 4,378 | $8K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 69 | $8K |
| 83970 | <1% | 328 | $8K | |
| 82746 | <1% | 1,557 | $8K | |
| 96376 | <1% | 2,119 | $8K | |
| 72040 | <1% | 242 | $7K | |
| 49083 | <1% | 31 | $7K | |
| 73610 | <1% | 1,417 | $7K | |
| 85610 | <1% | 2,499 | $7K | |
| 83516 | <1% | 250 | $7K | |
| 73560 | <1% | 722 | $6K | |
| 84425 | <1% | 753 | $6K | |
| 73221 | <1% | 42 | $6K | |
| 86901 | <1% | 1,892 | $6K | |
| 82947 | <1% | 1,486 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 31 | $6K |
| 84703 | <1% | 2,043 | $6K | |
| 82570 | <1% | 799 | $6K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 18 | $6K |
| 86592 | <1% | 435 | $6K | |
| 86038 | <1% | 322 | $6K | |
| 88307 | <1% | 42 | $6K | |
| 82784 | <1% | 464 | $5K | |
| 87040 | <1% | 2,571 | $5K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 32 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 21 | $5K |
| 84134 | <1% | 604 | $5K | |
| 87340 | <1% | 357 | $5K | |
| 82525 | <1% | 327 | $5K | |
| 73110 | <1% | 868 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,335 | $5K |
| 76820 | <1% | 428 | $5K | |
| 97165 | <1% | 160 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,265 | $5K |
| 97803 | <1% | 48 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 42 | $5K |
| 81003 | <1% | 4,194 | $5K | |
| 86039 | <1% | 192 | $5K | |
| 11045 | <1% | 25 | $4K | |
| 84550 | <1% | 682 | $4K | |
| 76937 | <1% | 398 | $4K | |
| 86703 | <1% | 130 | $4K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 59 | $4K |
| 82962 | <1% | 4,786 | $4K | |
| 84100 | <1% | 1,263 | $4K | |
| 84520 | <1% | 1,244 | $4K | |
| 70498 | <1% | 73 | $3K | |
| 83615 | <1% | 359 | $3K | |
| 80074 | <1% | 149 | $3K | |
| 73590 | <1% | 543 | $3K | |
| 87081 | <1% | 497 | $3K | |
| 76821 | <1% | 188 | $3K | |
| 76801 | <1% | 106 | $3K | |
| 81025 | <1% | 3,972 | $3K | |
| 85730 | <1% | 1,450 | $2K | |
| 77336 | <1% | 24 | $2K | |
| 72072 | <1% | 118 | $2K | |
| 85652 | <1% | 727 | $2K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 890 | $2K |
| 80051 | <1% | 837 | $2K | |
| 72220 | <1% | 54 | $2K | |
| 80143 | <1% | 1,667 | $2K | |
| 84590 | <1% | 309 | $2K | |
| 72128 | <1% | 83 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 140 | $2K |
| 73700 | <1% | 21 | $2K | |
| 82043 | <1% | 448 | $2K | |
| 71101 | <1% | 227 | $2K | |
| 84153 | <1% | 109 | $2K | |
| 82565 | <1% | 1,241 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 97014 | <1% | 81 | $2K | |
| 93880 | <1% | 25 | $2K | |
| 80076 | <1% | 549 | $2K | |
| 82248 | <1% | 1,116 | $2K | |
| 88342 | <1% | 536 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 228 | $2K |
| 84436 | <1% | 482 | $2K | |
| 82465 | <1% | 234 | $2K | |
| 77080 | <1% | 39 | $2K | |
| 86308 | <1% | 318 | $2K | |
| 36430 | <1% | 47 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 111 | $2K |
| 73070 | <1% | 301 | $2K | |
| 85651 | <1% | 405 | $2K | |
| 82044 | <1% | 220 | $2K | |
| 72050 | <1% | 36 | $2K | |
| 87210 | <1% | 665 | $2K | |
| 73090 | <1% | 297 | $2K | |
| 76641 | <1% | 13 | $1K | |
| 87634 | <1% | 739 | $1K | |
| 81002 | <1% | 8,562 | $1K | |
| 80164 | <1% | 131 | $1K | |
| 85378 | <1% | 744 | $1K | |
| 82378 | <1% | 120 | $1K | |
| 84478 | <1% | 301 | $1K | |
| 87077 | <1% | 941 | $1K | |
| 86481 | <1% | 29 | $1K | |
| 82077 | <1% | 657 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 55 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,062 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,301 | $1K |
| 82550 | <1% | 915 | $1K | |
| 80179 | <1% | 1,646 | $1K | |
| 86762 | <1% | 63 | $1K | |
| 84156 | <1% | 256 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,975 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 13,202 | $1K |
| 85014 | <1% | 395 | $903.41 | |
| 82805 | <1% | 35 | $890.24 | |
| 86706 | <1% | 35 | $886.10 | |
| 82977 | <1% | 86 | $880.23 | |
| 77066 | Tomosynthesis, mammo | <1% | 44 | $878.78 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 15 | $871.64 |
| 86317 | <1% | 48 | $852.75 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,488 | $822.47 |
| 85379 | <1% | 1,202 | $815.93 | |
| 97162 | <1% | 12 | $769.89 | |
| 64494 | <1% | 221 | $729.84 | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $728.78 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,636 | $705.20 |
| 87807 | <1% | 756 | $700.25 | |
| 84145 | <1% | 180 | $673.70 | |
| 00840 | <1% | 106 | $610.84 | |
| 88304 | <1% | 1,100 | $607.43 | |
| 87186 | <1% | 405 | $606.82 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 127 | $583.12 |
| 72170 | <1% | 133 | $578.36 | |
| 85018 | <1% | 396 | $568.93 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 15 | $531.50 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,539 | $522.10 |
| 82140 | <1% | 155 | $509.21 | |
| 84460 | <1% | 72 | $505.25 | |
| 82105 | <1% | 68 | $498.66 | |
| 86431 | <1% | 29 | $497.97 | |
| 73552 | <1% | 44 | $473.27 | |
| C1781 | Mesh (implantable) | <1% | 134 | $456.16 |
| 94618 | <1% | 14 | $436.34 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 125 | $426.07 |
| 86787 | <1% | 15 | $392.45 | |
| 87070 | <1% | 665 | $372.80 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,414 | $366.49 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,238 | $350.28 |
| 87205 | <1% | 598 | $325.90 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,216 | $318.73 |
| 90715 | <1% | 16 | $317.61 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 80 | $316.37 |
| 86704 | <1% | 19 | $309.65 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 870 | $304.30 |
| 87075 | <1% | 177 | $292.24 | |
| 90688 | <1% | 47 | $277.60 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,484 | $264.89 |
| 82010 | <1% | 625 | $264.30 | |
| 94664 | <1% | 415 | $261.36 | |
| 84146 | <1% | 26 | $252.64 | |
| 73060 | <1% | 43 | $252.02 | |
| 82951 | <1% | 12 | $245.96 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 18 | $228.15 |
| 84481 | <1% | 15 | $224.52 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,935 | $215.32 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,766 | $208.03 |
| 01992 | <1% | 210 | $202.68 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 674 | $178.94 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 65 | $177.27 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,309 | $170.24 |
| 82800 | <1% | 576 | $169.90 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 772 | $151.70 |
| 82150 | <1% | 53 | $142.31 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 540 | $131.45 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 270 | $124.91 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 295 | $124.38 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,249 | $112.63 |
| 73080 | <1% | 13 | $109.88 | |
| 74022 | <1% | 31 | $108.84 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 409 | $106.69 |
| 84165 | <1% | 17 | $101.37 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,298 | $95.81 |
| 84112 | <1% | 13 | $83.84 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,446 | $73.49 |
| 73521 | <1% | 14 | $70.41 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,873 | $66.72 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 598 | $65.73 |
| 84155 | <1% | 17 | $64.86 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 606 | $62.78 |
| 86923 | <1% | 16 | $60.54 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 198 | $46.57 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 247 | $36.76 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 548 | $34.77 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 110 | $30.21 |
| 86403 | <1% | 35 | $30.10 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 368 | $27.87 |
| J1921 | Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg | <1% | 68 | $25.56 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 201 | $24.91 |
| 84132 | <1% | 29 | $20.98 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 173 | $20.24 |
| G0008 | Administration of influenza virus vaccine | <1% | 66 | $19.81 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 118 | $13.24 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 131 | $12.99 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,220 | $12.90 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 304 | $11.02 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 536 | $9.49 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 73 | $8.96 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 91 | $8.86 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 48 | $7.20 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 138 | $6.85 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 293 | $4.96 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 85 | $4.58 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14 | $4.52 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 208 | $4.49 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,302 | $3.46 |
| 82731 | <1% | 16 | $3.22 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 789 | $1.84 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 65 | $1.35 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 34 | $0.31 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,703 | $0.18 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 321 | $0.00 |
| 00790 | 0% | 615 | $0.00 | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | 0% | 126 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 538 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 82 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 112 | $0.00 |
| 64484 | 0% | 31 | $0.00 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 35 | $0.00 |
| 00630 | 0% | 16 | $0.00 | |
| 96368 | 0% | 41 | $0.00 | |
| 01480 | 0% | 113 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 256 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 31 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 26 | $0.00 |
| 94761 | 0% | 28 | $0.00 | |
| 94760 | 0% | 27 | $0.00 | |
| 01400 | 0% | 19 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 76 | $0.00 |
| 29125 | 0% | 44 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 275 | $0.00 |
| 74300 | 0% | 36 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 14 | $0.00 |
| H1000 | Prenatal care, at-risk assessment | 0% | 53 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 15 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 29 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 17 | $0.00 |
| 76818 | 0% | 112 | $0.00 | |
| 64495 | 0% | 58 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 210 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 16 | $0.00 |
| 01810 | 0% | 29 | $0.00 | |
| 00400 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.